- About
-
Projects
-
Column 1
- Advancing Regulatory Science
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
-
Column 2
- Food & Nutrition
- Improving Access to FDA Information
- Research
- Substance Use Disorders
-
Column 1
- News and Events
- Expanded Access eRequest
Upcoming Events
This informational webinar will offer a “101-level” overview of how the expanded access process works.
Join our discussion with outsourcing facility executives and a group purchasing organization about developing a portfolio, including how to maintain and evolve a portfolio and how customer relationships and operational capacity factor into decision making.
Join us for a discussion with outsourcing facility executives and consultants on how to embed quality across the organization.
Join us for our 10th annual Awards celebration!
Past Events
The Foundation, in collaboration with the U.S. Food and Drug Administration, convened a hybrid public meeting to discuss opportunities to expand treatment options for patients by identifying new uses for approved drugs.
Each year, the Reagan-Udall Foundation for the FDA’s Board of Directors conducts an annual public meeting to highlight the Foundation’s activities in support of the U.S. Food and Drug Administration.
On May 27, 2026, the Reagan-Udall Foundation for the FDA convened a hybrid public meeting on Exploring Regulatory Constructs for Gerotherapeutic Drug Development to discuss potential regulatory constructs.
With the growing public appreciation of accessible health care solutions, this public meeting fostered collaboration, explored critical gaps, and illuminated pathways for the development, review, and deployment of at-home diagnostic devices to improve health care access, and advance the home as a hub of health care.
On February 26, 2026, the Reagan-Udall Foundation for the FDA will convene a hybrid public meeting on Advancing Drug Development by Reducing Reliance on Animal Testing.
The Reagan-Udall Foundation for the FDA, in collaboration with the Milken Institute’s Women’s Health Network, convened an in-person, invitation-only roundtable to discuss unmet needs in women’s health drug development.
The Foundation collaborated with the FDA Compounding Quality Center of Excellence to convene a virtual discussion on managing quality and risk.
The Food and Drug Administration (FDA) and the Reagan-Udall Foundation were pleased to host the sixth Online Controlled Substances Summit on September 11, 2025.
On August 27, 2025, the Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a hybrid public meeting on "Demand Forecasting for Controlled Substances.” This meeting included exploration of the complex factors that are considered when estimating the medical, scientific, and reserve stock needs for Schedule I and Schedule II substances, such as opioids and stimulants.
The Reagan-Udall Foundation for the FDA, in cooperation with the Food and Drug Administration, convened a hybrid public meeting to gather input on the clinical use and safety concerns associated with orally ingestible unapproved prescription drug products containing fluoride for use in children.